LLY

785.76

-1.21%↓

JNJ

152.76

+0.26%↑

ABBV

186.41

-0.43%↓

NVO

68.78

+2.32%↑

UNH

307.81

+1.17%↑

LLY

785.76

-1.21%↓

JNJ

152.76

+0.26%↑

ABBV

186.41

-0.43%↓

NVO

68.78

+2.32%↑

UNH

307.81

+1.17%↑

LLY

785.76

-1.21%↓

JNJ

152.76

+0.26%↑

ABBV

186.41

-0.43%↓

NVO

68.78

+2.32%↑

UNH

307.81

+1.17%↑

LLY

785.76

-1.21%↓

JNJ

152.76

+0.26%↑

ABBV

186.41

-0.43%↓

NVO

68.78

+2.32%↑

UNH

307.81

+1.17%↑

LLY

785.76

-1.21%↓

JNJ

152.76

+0.26%↑

ABBV

186.41

-0.43%↓

NVO

68.78

+2.32%↑

UNH

307.81

+1.17%↑

Search

Viatris Inc

Open

SectorHealthcare

9.08 0.11

Overview

Share price change

24h

Current

Min

9.04

Max

9.15

Key metrics

By Trading Economics

Income

-2.5B

-3B

Sales

-274M

3.3B

EPS

0.5

Dividend yield

5.42

Profit margin

-93.476

Employees

32,000

EBITDA

-2.7B

-2.3B

Recommendations

By TipRanks

Recommendations

Sell

12 Months Forecast

+1.24% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

5.42%

2.40%

Next Earnings

7 sie 2025

Next Dividend date

12 wrz 2025

Next Ex Dividend date

22 sie 2025

Market Stats

By TradingEconomics

Market Cap

539M

10B

Previous open

8.97

Previous close

9.08

News Sentiment

By Acuity

50%

50%

154 / 380 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

Viatris Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

26 cze 2025, 23:49 UTC

Earnings

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

26 cze 2025, 22:19 UTC

Acquisitions, Mergers, Takeovers

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

26 cze 2025, 21:30 UTC

Earnings

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

26 cze 2025, 21:07 UTC

Earnings

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

26 cze 2025, 23:49 UTC

Market Talk

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

26 cze 2025, 23:39 UTC

Market Talk

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

26 cze 2025, 23:34 UTC

Acquisitions, Mergers, Takeovers

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

26 cze 2025, 23:33 UTC

Acquisitions, Mergers, Takeovers

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

26 cze 2025, 23:32 UTC

Acquisitions, Mergers, Takeovers

Wesfarmers Will No Longer Receive Earnings From BWP Management

26 cze 2025, 23:32 UTC

Acquisitions, Mergers, Takeovers

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

26 cze 2025, 23:31 UTC

Acquisitions, Mergers, Takeovers

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

26 cze 2025, 23:31 UTC

Acquisitions, Mergers, Takeovers

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

26 cze 2025, 23:30 UTC

Acquisitions, Mergers, Takeovers

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

26 cze 2025, 23:29 UTC

Acquisitions, Mergers, Takeovers

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

26 cze 2025, 23:19 UTC

Acquisitions, Mergers, Takeovers

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

26 cze 2025, 22:06 UTC

Earnings

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 cze 2025, 21:15 UTC

Earnings

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

26 cze 2025, 21:07 UTC

Acquisitions, Mergers, Takeovers

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

26 cze 2025, 21:07 UTC

Acquisitions, Mergers, Takeovers

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

26 cze 2025, 21:07 UTC

Acquisitions, Mergers, Takeovers

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

26 cze 2025, 21:07 UTC

Earnings

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 cze 2025, 21:06 UTC

Acquisitions, Mergers, Takeovers

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

26 cze 2025, 21:06 UTC

Acquisitions, Mergers, Takeovers

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

26 cze 2025, 21:06 UTC

Market Talk

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

26 cze 2025, 21:05 UTC

Acquisitions, Mergers, Takeovers

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 cze 2025, 21:05 UTC

Acquisitions, Mergers, Takeovers

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 cze 2025, 20:52 UTC

Earnings

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

26 cze 2025, 20:51 UTC

Earnings

Correct: Nike 4Q Net $211M, Not $200M >NKE

26 cze 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26 cze 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

Peer Comparison

Price change

Viatris Inc Forecast

Price Target

By TipRanks

1.24% upside

12 Months Forecast

Average 9 USD  1.24%

High 10 USD

Low 8 USD

Based on 3 Wall Street analysts offering 12 month price targets forViatris Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Sell

3 ratings

0

Buy

2

Hold

1

Sell

Technical Score

By Trading Central

8.48 / N/ASupport & Resistance

Short Term

Bullish Evidence

Intermediate Term

Very Strong Bullish Evidence

Long Term

Strong Bearish Evidence

Sentiment

By Acuity

154 / 380 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Viatris Inc

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.